Noninvasive Prenatal Testing

Whole genome sequencing of cell-free DNA for NIPT

May 05, 2021

An analysis of a large cohort of patients who chose noninvasive prenatal testing (NIPT) as a screening method for fetal trisomy 21, 18, and 13 (T21, T18 and T13) and sex chromosome aneuploidies (SCA) concluded there were extremely high detection rates and exceptionally low false positive rates.

Economic impact of coverage expansion for NIPT

April 15, 2021

Expanding coverage for noninvasive prenatal testing (NIPT) through a performance-based, risk-sharing agreement (PBRSA) resulted in a significant increase in NIPT use, a significant decrease in conventional prenatal screening methods, and a negligible increase in per member per month (PMPM) cost at Harvard Pilgrim Health Care (HPHC) in New England.

Cost of cell-free DNA noninvasive testing for Down syndrome

March 09, 2021

A public health screening program for Down syndrome in Quebec, Canada, found that cell-free DNA noninvasive prenatal testing (NIPT) could be implemented at the same cost as the current screening program, according to computer simulations.

Expanding scope of noninvasive prenatal testing

February 23, 2021

“Our results can further inform the debate on the future uses of NIPT and future policy of its implementation,” said co-principal investigator Hazar Haidar, PhD, a lecturer in bioethics at Université du Québec à Montréal (UQAM), Montréal, Canada.

Fetal aneuploidy screening with a noninvasive prenatal test

February 01, 2021

A population-based register study from the Netherlands has found that the percentage of pregnant women opting for fetal aneuploidy screening reached a high of 45.9% within 1 year after the introduction in 2017 of a noninvasive prenatal test (NIPT) as a first-tier test for all women.